Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis
Open Access
Abstract
The overall prognosis for sarcoma-based cancer patients has remained largely unchanged over the past 10 years. Because there is no effective anticancer drug for patients with chemoresistant osteosarcoma (OS), novel approaches are needed to improve the prognosis. Here, we investigated whether rapamycin (Rapa) could enhance the anti-tumor effects of gemcitabine (Gem) in OS. Gem dose-dependently killed the OS cells, but exhibited much lower cytotoxicity on osteoblasts. Treatment with a combination Gem and Rapa was much more effective than that of either single agent with respect to reducing cell viability, cell invasion, cell migration, and vascular endothelial growth factor production in vitro. Moreover, the combination of these agents suppressed tumor growth, angiogenesis, and lung metastasis in allograft and xenograft murine models of OS with minimal adverse effects. Overall, the combination therapy prolonged the overall survival of tumor-bearing mice. Mechanistically, Gem induced apoptosis and increased the levels of cleaved caspases, while Rapa induced autophagy and microtubule-associated protein light chain 3 (LC3)-I/LC3-II expression both in vitro and in vivo. Our findings suggest that chemotherapy using Gem combined with Rapa may be a novel and promising therapeutic approach for the treatment of OS.Keywords
Funding Information
- Japan Society for the Promotion of Science (16K10851, 18K09060, 19K09594, 20K17995, 20K18027)
This publication has 54 references indexed in Scilit:
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryBreast Cancer Research and Treatment, 2013
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue SarcomasJournal of Clinical Oncology, 2012
- Mechanisms Involved in the Coordinate Regulation of mTORC1 by Insulin and Amino AcidsJournal of Biological Chemistry, 2011
- OsteosarcomaAnnals of Oncology, 2010
- mTOR regulation of autophagyFEBS Letters, 2010
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patientsCancer, 2009
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcomaCancer, 2008
- Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and FutureThe Oncologist, 2007
- Autophagy and signaling: their role in cell survival and cell deathCell Death & Differentiation, 2005
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004